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Abstract
AIM
To develop a screening test for celiac disease based on 
the coating of gold nanoparticles with a peptide sequence 
derived from gliadin, the protein that triggers celiac dis-
ease. 
METHODS
20 nm gold nanoparticles were first coated with Neutr-
Avidin. A long chain Polyethylene glycol (PEG) linker con-
taining Maleimide at the Ω-end and Biotin group at the 
α-end was used to ensure peptide coating to the gold 
nanoparticles. The maleimide group with the thiol (-SH) 
side chain reacted with the cysteine amino acid in the 
peptide sequence and the biotinylated and PEGylated 
peptide was added to the NeutrAvidin coated gold nano-
particles. The peptide coated gold nanoparticles were 
then converted into a serological assay. We used the 
peptide functionalised gold nanoparticle-based assay on 
thirty patient serum samples in a blinded assessment and 
compared our results with the previously run serological 
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and pathological tests on these patients.
RESULTS
A stable colloidal suspension of peptide coated gold 
nanoparticles was obtained without any aggregation. 
An absorbance peak shift as well as color change was 
caused by the aggregation of gold nanoparticles following 
the addition of anti-gliadin antibody to peptide coated 
nanoparticles at levels associated with celiac disease. The 
developed assay has been shown to detect anti-gliadin 
antibody not only in quantitatively spiked samples but also 
in a small-scale study on real non-hemolytic celiac disease 
patient’s samples.
CONCLUSION
The study demonstrates the potential of gold nanoparticle-
peptide based approach to be adapted for developing a 
screening assay for celiac disease diagnosis. The assay 
could be a part of an exclusion based diagnostic strategy 
and prove particularly useful for testing high celiac disease 
risk populations. 
Key words: Celiac disease; Serological point-of-care; Gold 
nanoparticles; Diagnostic test; Autoantibodies
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In the present study, we demonstrated that a 
peptide sequence derived from gliadin, a hydrophobic 
whole protein that induces celiac disease, in conjunction 
with gold nanoparticles can be used to detect a biomarker 
for celiac disease from serum. We confirmed our gold 
nanoparticle based serological assay can detect anti-
gliadin antibody not only in quantitatively spiked samples 
but also in a small-scale study on real non-hemolytic 
celiac disease patient’s samples. 
Kaur A, Shimoni O, Wallach M. Novel screening test for celiac 
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Sensing platforms based on the optical properties of 
gold nanoparticles (AuNPs) for the molecular detection 
and recognition of disease biomarkers is an important re­
search challenge. Colorimetric sensors based on AuNPs 
have been applied for detecting targets, such as metal 
ions[1­4], DNA[5,6], protein conformations[7] and enzyme 
activity[8], where they have demonstrated high sensitivity 
and effectiveness. 
In recent years, newer designs of nanoparticles with 
enhanced and controlled surface chemistry are being 
explored for sensing applications. Peptide­functionalized 
nanoparticles (PFNs) are one such emerging sensing 
element. PFNs have previously been used for effective 
drug delivery for treating brain tumors and for pancreatic 
cancer treatment as well as for kinase inhibitor screen­
ing[9,10,11­12]. Here we demonstrate the potential of PFNs 
as a colorimetric sensor for screening celiac disease. 
Celiac disease (CD) is a small intestine enteropathy 
affecting genetically susceptible individuals, following 
the consumption of wheat prolamins (gliadin) and other 
prolamins of cereals[13]. Population based studies have 
predicted a high prevalence rate for the disease, with a 
large number of CD sufferers remaining undiagnosed[14]. 
The current diagnosis of CD is based on mucosal biopsy 
that remains the gold standard[15]. Serological testing 
for gliadin­induced antibodies using an enzyme­linked 
immunosorbent assay is being widely applied[16,17] and is 
usually the first line in clinical diagnosis for CD.
Gliadin antigenicity arises due to the higher content 
and repetitive arrangement of amino acids glutamine 
(~36 %) and proline (~17%­23%)[18]. This acts as 
the substrate for the enzyme tissue transglutaminase 
(tTG: EC 2.3.2.13), resulting in deamidation and 
formation of an irreversible isopeptidyl bond[19]. Human 
Leukocyte Antigen­DQ molecules (HLA­DQ2/8) present 
the deamidated gliadin peptides (DGP) to mucosal 
CD4+ T cells leading to an immunostimulatory effect[20]. 
Gluten reactive helper T cells support the activated 
CD4+ T cells in the intestinal mucosa leading to the 
release of autoantibodies that act as the serological 
biomarkers[21,22].
Non­treated CD patients have been shown to have 
increased concentration of anti­gliadin (AGA), tTG anti­
bodies as well as Anti­DGP antibodies[23,24]. A deamidated 
peptide sequence derived from α­gliadin amino acids 
57-73 has also been identified as an immunogenic pep-
tide sequence that can act as a trigger for CD[25].
In this paper, we present a screening test for CD 
using gold nanoparticles (AuNPs) coated with a peptide 
sequence derived from the gliadin protein. We first estab-
lished a stable suspension (without any significant level 
of aggregation) of peptide coated AuNPs, which enables 
us to translate it to a serological assay. We next assessed 
the sensitivity and specificity levels of the test using 
serum samples spiked with AGA. Furthermore, we tested 
our assay on thirty patient serum samples and found 
that the PFN­based assay could distinguish CD from non­
CD patients. 
This study highlights the potential of using immuno­
dominant and biomarker specific peptide sequences 
that can be used for developing an efficient, easy to use 
screening test for pre­selecting CD cases, which can be 
then confirmed by mucosal biopsy for CD. 
MATERIALS AND METHODS
Reagents: 20 nm citrate stabilized gold nanoparticles 
(AuNPs), bovine serum albumin (BSA), AGA from 
rabbit, IgG antibody from whole normal rabbit serum, 
4­(2­hydroxyethyl)­1­piperazineethanesulfonic acid 
(HEPES), phosphate­buffered saline (PBS) were ob­
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tained from Sigma­Aldrich (Australia). Poly (ethylene 
glycol) [N­(2­maleimidoethyl) carbamoyl] methyl ether 
2­(biotinylamino) ethane (i.e., Biotin­PEG11­Maleimide) 
and NeutrAvidin were obtained from Thermo Fisher Scien­
tific (Australia).
Peptide: The Peptide (QLQPFPQPQLPYPQPQC) was 
synthesised from ChinaPeptides Co., Ltd. (China). The 
synthetic crude peptides were purified by reversed­
phase liquid chromatography to give satisfactory peptide 
sequence (~90% homogeneity by analytical HPLC) with 
the correct amino acid sequences and mass spectra. The 
peptide contained residues 57­72 of α­gliadin and was 
designated as follows: Peptide: QLQPFPQPQLPYPQPQC. 
The peptide (QLQPFPQPQLPYPQPQC) was coated on 
the surface of the AuNPs in two stages: First, coating 
with NeutrAvidin followed by a second step of binding of 
the peptide through a biotin­PEG11­Maleimide linker mole­
cule. 
Preparation of the AuNPs coated with NeutrAvidin: 
300 μL of 20 nm AuNP were added dropwise to 200 μL 
of NeutrAvidin dissolved in 10mM HEPES (1 mg/mL) 
while vortexing. The tube was incubated for 60 min at 
room temperature with repeated vortexing. The solution 
was centrifuged for 30 min at 4500 × g, supernatant 
discarded, and the pellet was re­suspended in 200 μL 
MilliQ water. The process was repeated twice after which 
the pellet was re­suspended in 200 μL HEPES buffer 
followed by centrifugation at 4500 × g for 30 min using 
an Eppendorf® Microcentrifuge. The NeutrAvidin coated 
AuNPs were stored at 4 ℃. 
Binding of peptide to linker molecule: 300 μL of 0.5 
mg/mL peptide (QLQPFPQPQLPYPQPQC) dissolved in 
MilliQ water was added dropwise to 700 μL of 0.5 mg/mL 
Poly (ethylene glycol) [N­(2­maleimidoethyl) carbamoyl] 
methyl ether 2­(biotinylamino) ethane (i.e., Biotin­PEG­
Maleimide) dissolved in MilliQ water, (Mn 5400, MW 921 
Da) having maleimide at the Ω­end and biotin at the α­end. 
This solution was left overnight at room temperature.
Preparation of the AuNPs coated with peptide 
using linker: The NeutrAvidin coated AuNPs were cen­
trifuged at 4500 × g for 30 min using an Eppendorf® 
microcentrifuge, supernatant discarded, the pellet was 
re­suspended in 100 μL of the peptide­linker solution. 
The tube was incubated for 60 min at room temperature 
with repeated vortexing. The solution was centrifuged for 
5 min at 4500 × g, supernatant was discarded, and the 
pellet was re­suspended in 100 μL of MilliQ water. The 
peptide coated AuNPs were stored at 4 ℃ for up to 4 wk. 
Dynamic light scattering (DLS): The nanoparticle 
hydrodynamic radius was measured using Zetasizer 
Nano (Malvern Technologies, Inc.). Measurements were 
carried out at 25 ℃ in disposable cuvettes using a sample 
volume of 500 μL. Each sample was measured in dupli­
cates and the mean value was calculated.
Transmission electron microscopy: High­resolution 
transmission electron microscopy (TEM) micrographs 
were obtained using a FEI Tecnai TEM 200V fitted with 
a Gatan (Pleasantville, CA, United States) CCD camera. 
Samples were prepared by placing 2 μL of AuNP coated 
with peptide onto a carbon­coated TEM grid (Agar 
Scientific, United Kingdom) and the film allowed to air 
dry for 15 min.
UV-vis measurements: UV­vis measurements were 
carried out using a Cary series UV­vis spectrophotometer 
(Agilent Technologies) using a standard 1 cm path­length 
quartz cuvette. Spectra were obtained from 200 nm to 
800 nm. MilliQ water was used as the blank.
Anti-gliadin assay: The immunoassay used to assess 
the activity of AuNPs coated with peptide with the 
antibodies is outlined below. Assay steps were performed 
at room temperature. Briefly, 150 μL of AuNPs coated 
with peptide were added to 1.5 mL low protein binding 
Eppendorf® tubes. AGA (1 mg/mL) from rabbit was added 
to each of the tubes corresponding to concentrations 
ranging from 2 μg/mL to 20 μg/mL (i.e., 1 μL to 10 μL) to 
determine the specificity of the reaction between peptide 
coated AuNPs and AGA. IgG from normal rabbit serum 
(1 mg/mL) was used as a control antibody and added to 
150 μL of AuNPs coated with peptide in concentrations 
ranging from 2 μg/mL to 20 μg/mL (i.e., 1 μL to 10 μL). 
MilliQ water was added to the tubes to bring the final 
volume in each Eppendorf tube up to 225 μL. The UV­vis 
absorption spectra of solutions containing peptide coated 
gold nanoparticles and AGA at increasing dilutions (2 μg/
mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL, 12 μg/mL, 
14 μg/mL, 16 μg/mL, 18 μg/mL and 20 μg/mL) were 
studied using a Cary Series UV­vis spectrophotometer. 
Readings were taken in triplicate and the student’s t­test 
was used to determine the P value.
Anti-gliadin assay in spiked human serum: Nor­
mal human serum was diluted to 1:20 using 10 mmol/L 
HEPES buffer. 75 μL of serum from the dilution was 
spiked with AGA at various dilutions comparable to that 
seen in celiac patients. 
To prevent non­specific binding, 1 μL of 20% BSA 
dissolved in MilliQ water and was added to 150 μL of 
20 nm AuNPs coated with peptide. The tubes were 
incubated for 30 min room temperature. 75 μL of normal 
serum spiked with AGA at increasing dilutions of 2 
μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL and 10 μg/mL, 12 
μg/mL, 14 μg/mL, 16 μg/mL, 18 μg/mL and 20 μg/mL 
was then added to AuNPs coated with peptide. The tubes 
were then incubated for 30 min room temperature. 
Anti-gliadin assay in clinical human serum: Anony­
mised patient samples were provided by Dr Jason Tye­
Din from the Walter and Eliza Hall Institute of Medical 
Research (WEHI Institute, Melbourne Parkville, Australia). 
They were collected with informed consent and approval 
of Melbourne Health and WEHI Human Research Ethic 
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presented in Tables 1 and 2.
Prior to testing, each human serum sample was 
diluted to 1:10, 1:20 and 1:50 using 10 mmol/L HEPES 
buffer. 1 μL of 20% BSA dissolved in MilliQ water was 
added to AuNPs coated with peptide to prevent non­
specific binding. 75 μL of serum from each of the dilu­
tions and the tubes were incubated for 15 min at room 
temperature before the absorbance was measured using 
a UV­vis spectrophotometer.
Concentration of immunoglobulins in clinical hu-
man serum: 200 μL of each human serum sample was 
centrifuged at 3200 × g or 15 min. The supernatant was 
removed, and the serum samples were diluted with 200 
μL of 10 mmol/L PBS. An equal volume of saturated 
ammonium sulphate solution was added slowly to achi­
Committees (2003.009 and 03/04) respectively. Ethical 
approval was also obtained from the University of 
Technology Sydney Research Ethics committee (UTS 
HREC ETH16 ­ 0841) before testing the clinical samples. 
The clinical samples consisted of 30 human serum sam­
ples that were analyzed in a blinded assessment. No 
prior knowledge of the CD status or any other clinical 
condition for any of the patient samples was known while 
testing. Samples were collected from patients with active 
CD (pre­treatment), treated CD (on a gluten free diet) 
and controls without CD (Tables 1 and 2). All cases of 
CD were medically diagnosed and based on typical small 
intestinal histology usually in conjunction with positive CD 
serology. The histological interpretation and the serology 
levels for each of the clinical sample tested using biopsy 
and the existing commercially available serology tests is 
Volunteer Histology   tTG-IgA DGP-IgG AuNP-peptide-AGA test
n.1 CD        1 (< 4)        3 (< 20) CD positive
n.21 Non-CD     0.1 (0-6)   0.2 (0-6) CD positive
n.3 CD > 100 (< 4)      33 (< 20) CD positive
n.4 CD      121 (< 20) CD positive
n.5 CD > 100 (< 4) > 100 (< 20) CD positive
n.6 CD    217 (< 5) > 150 (< 20) CD positive
n.72 CD      13 (0-6)    23 (0-6) CD negative
n.8 CD > 100 (< 5) > 100 (< 20) CD positive
n.9 CD      11 (0-6)   1.4 (0-6) CD positive
n.10 CD        9 (< 4)      97 (< 20) CD positive
n.11 CD        18.2 (0 < 20)        3 (0.20) CD positive
n.12 CD        16 (0-20)        7 (< 20) CD positive
n.13 Non-CD          4 (0-20) Non-CD
n.14 CD      47 (< 5)    86 (< 5) CD positive
n.152 CD        74 (0-20) CD negative
n.16 CD      145 (0-20) CD positive
n.17 CD      57 (< 4)      93 (< 20) CD positive
n.18 CD     149 (<20)      63 (< 20) CD positive
n.19 CD > 100 (< 4) > 100 (< 20) CD positive
n.201 Non-CD     3.8 (< 6)    37 (< 6) CD positive
n.21 Non-CD     < 5 (< 5)   < 20 (< 20) Non-CD
n.22 CD    180 (0-6)    21 (0-6) CD positive
n.23 CD      20 (0-6)   8.1 (0-6) CD positive
Table 1  Comparison of the patient samples analysis using the AuNP-peptide-anti-gliadin test with previously existing histology and 
serological1 results
1False positive based on histology and tTG antibody titre, 2False negative based on histology and tTG antibody titre. Serology tTG (Tissue transglutaminase), 
deamidated gliadin peptides (deaminated gliadin peptides) results are indicated as IgA or IgG levels followed by normal reference ranges in brackets.
Volunteer Histology tTG-IgA DGP-IgG Peptide-AuNP-AGA
n.24 Mucosal lesions      5 (< 20)    17 (< 20) CD positive
n.25 Mucosal lesions  28 (0-6)  22 (0-6) CD positive
n.26 Mucosal lesions 4.8 (0-6)  22 (0-6) CD positive
n.27 Increased γδ+ IELs < 5 (< 5)    22 (< 20) CD positive
n.28 Increased γδ+ IELs  12 (0-6)  18 (0-6) CD positive
n.29 Increased γδ+ IELs  11 (0-6)  13 (0-6) CD positive
n.30 Increased γδ+ IELs < 5 (< 5) < 20 (< 20) CD positive
Table 2  Analysis of 7 samples with potential or latent celiac disease using the Peptide-AuNP-anti-gliadin test as compared with 
previously existing serology1
1Serology tTG (tissue transglutaminase), deamidated gliadin peptides (deaminated gliadin peptides) results are indicated as IgA or IgG levels followed by 
normal reference ranges in brackets. Cases are separated into those showing histological observations of irregular/patchy mucosal lesions or those with 
mucosal inflammation resulting from an increase in γδ+ IELs.
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eve a 33% saturated (v/v) final concentration with con-
tinuous stirring of the tubes. Samples were kept at 4 ℃ 
for 30 min and then centrifuged again at 2500 × g for 15 
min. The supernatant was removed, and the pellet was 
re­suspended by adding 200 μL of 10 mmol/L PBS. The 
concentrated serum solution was stored at 20 ℃ till fur­
ther use.
Zeba™ Spin desalting columns (Thermo Scientific™) 
were used for the de salting of the immunoglobulins from 
the concentrated serum solution according to the manu­
facturer’s instructions. The final concentration of the total 
immunoglobulins was measured using the NanoDrop and 
stored at ­20 ℃ until further use.
Colorimetric response curve: A colorimetric response 
curve was plotted to represent the sensitivity values 
obtained for the different dilution values for both the 
AGA and the control antibody (IgG from rabbit serum). 
The assay sensitivity was determined based on the 
colorimetric response values calculated as colorimetric 
response = Imax at 527 nm/ Iat 550 nm, i.e., spectral absorbance 
value obtained at 527 nm ­ the wavelength where AuNP 
coated with peptide show maximum absorbance by itself 
(no antibodies are added) ­ divided by the absorbance 
at 550 nm, where a shift in absorbance is observed 
following the interaction of the antibody to the AuNP 
coated with peptide.
The assay sensitivity in spiked serum was calculated 
as colorimetric response = Imax at 580nm/Iat 527 nm, i.e., absor­
bance value obtained at 580 nm. This is the wavelength 
where a shift in absorbance is observed following the 
interaction of the antibody to the AuNP coated with 
peptide in serum divided by the maximum absorbance 
value of AuNP coated with peptide in serum.
RESULTS
To ensure the peptide coating on AuNPs, we used a 
long chain PEG linker containing Maleimide at the Ω­end 
and Biotin group at the α­end. Following the reaction 
of maleimide group with the thiol (­SH) side chain of 
the cysteine amino acid in the peptide sequence, the 
biotinylated and PEGylated peptide was added to the 
NeutrAvidin coated AuNPs.
The coating of the peptide sequence to the colloidal 
AuNP using the Biotin­(PEG)11­Maleimide linker is repre­
sented in the schematic (Figure 1).
The coating of peptide onto the AuNPs was cha­
racterized using the UV­vis spectrophotometer. It was 
observed that upon coating of peptide onto the AuNPs, 
there was a shift in absorbance maximum from 525 
nm to 527 nm (red­shift) (Figure 2A). The DLS showed 
an increase in hydrodynamic diameter from 20 nm to 




































AuNP-NeutrAvidin Biotin-(PEG)11-Maleimide-Peptide AuNP coated with Peptide
Figure 1  Schematic representation of preparation of peptide coated AuNPs. A: Maleimide groups of the linker reacted specifically with free (reduced) sulfhydryl’s in 
the peptide sequence to form stable thio-ether bonds; B: NeutrAvidin was coated on the surface of the AuNPs to obtain NeutrAvidin-AuNP particles; C: The biotin end 
of the linker interacted with the NeutrAvidin-AuNPs resulting in the formation of peptide coated AuNPs.
Biotin-(PEG)11-Maleimide-Peptide
C
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hydrodynamic diameter of NeutrAvidin coated AuNPs is 
presented in Supplementary Figure 1. 
To directly observe the coating of peptide onto the 
surface of the AuNPs, high­resolution TEM imaging was 
used. Our results showed the presence of a thin layer of 
material (< 1 nm) surrounding the nanoparticles [Figure 
2C (Ⅱ)], which was not observed on the surface of the 
uncoated nanoparticles [Figure 2C (Ⅰ)] that indicated 
peptide coating. As the layer was very thin, peptide 
coated and uncoated AuNPs were incubated with AGA (12 
μg/mL), wherein the peptide coated AuNPs aggregated 
[Figure 2D (Ⅰ, Ⅱ, Ⅲ)] while uncoated AuNPs remained 
dispersed [Figure 2D (Ⅳ, Ⅴ, Ⅵ)]. 
Incubation of peptide-coated AuNPs with AGA 
Peptide coated AuNPs were incubated with serial dilutions 
of rabbit anti­gliadin IgG polyclonal antibody, after 45 min 
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Figure 2  Characterization of peptide coated AuNPs. A: Characterization of AuNP coated with peptide using a UV-Vis spectrophotometer indicating a spectral 
red shift in wavelength from 525 nm (for 20 nm AuNP only) to 527 nm (for 20 nm AuNP coated with peptide); B: Characterization of AuNP coated with peptide using 
DLS that showed an increase in the hydrodynamic size of the uncoated vs coated particles from 20 nm to 28 nm respectively; C: High resolution TEM images of (1) 
uncoated AuNPs, (2) AuNPs coated with peptide showing a “halo” layer surrounding the surface of the nanoparticles indicating coating of the gold with the peptide had 
occurred. In contrast, the “halo” effect was not observed on the surface of the un-coated AuNPs; D: High resolution TEM images following the incubation with AGA 
(12 μg/mL) (1, 2, 3) AuNPs coated with peptide showing aggregation confirming coating of peptide on AuNP (4, 5, 6) Uncoated AuNPs remained dispersed. DLS: 
Dynamic light scattering; TEM: Transmission electron microscopy.
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as well as a shift in absorbance from 527 nm to 580 nm 
(Figure 3A and B, Supplementary Figure 2). 
To confirm the specificity of the interactions, we tested 
normal IgG antibody with the peptide coated AuNPs as 
a control, where we observed no significant reduction in 
color or shift in the wavelength or aggregation of AuNPs. 
(Figure 3A and B, Supplementary Figure 3). At all the 
tested concentrations, the absorbance was significantly 
lower using AGA as compared to normal IgG (P < 0.005, 
Figure 3B, Supplementary Table 1). 
To confirm the sensitivity of the AGA toward peptide 
coated AuNPs, we calculated a colorimetric response 
between our assay (Figure 3C). The colorimetric re­
sponse reaches a maximum value at a concentration 
of 8 μg/mL of AGA meaning the highest sensitivity oc­
curred at this concentration. This interaction of the pep­
tide coated AuNPs with AGA resembles the precipitin 
reaction of antibody­antigen immune complexes. The 
near constant colorimetric response curve obtained for 
the control antibody as compared to the response curve 
obtained for AGA demonstrates the distinct sensitivity of 
the assay.
Testing anti-gliadin in spiked serum 
A variety of proteins, peptides as well as nucleic acids are 
constituents of human serum, making it a complex fluid. 
To reduce background binding, we used 1 μL of 20% BSA 
as a blocking agent, to lower the non-specific interaction 
with the peptide coated AuNPs. Spiked human serum 
containing 2­20 μg/mL AGA was incubated with the pep­
tide coated AuNPs. The results showed an increase in ag­
gregation and precipitation, which was easily detectable 
by eye, with a specificity up to a value of 2 μg/mL of AGA 
(Figure 4A). We also observed a reduction in the color 
of the solution from red to translucent. This change was 
supported by the increase in the colorimetric response 
reaching a maximum sensitivity at 8 μg/mL of AGA. 
The curve then begins to drop off at 10 μg/mL of AGA, 
however, it remains well above the control IgG level 
(Figure 4B). In comparison, when normal rabbit IgG was 
added to the human serum, no precipitate formation 
or change in color was observed. Normal serum itself 
did not show any precipitate formation or change in 
absorbance with a constant response curve at all IgG con­
centrations. 
Figure 3  Testing peptide-coated AuNPs with anti-gliadin. A: Reduction in color from red to translucent and absorbance was observed in AuNP coated with peptide 
(S) and incubated with AGA at various dilutions (S1) 2 μg/mL, (S2) 4 μg/mL, (S3) 6 μg/mL, (S4) 8 μg/mL, (S5) 10 μg/mL), (S6) 12 μg/mL, (S7) 14 μg/mL, (S8) 16 
μg/mL, (S9) 18 µg/mL and (S10) 20 μg/mL. No significant reduction in color or shift in peak wavelength was observed in peptide coated AuNP incubated with control 
rabbit IgG at dilutions (C1) 2 μg/mL, (C2) 4 μg/mL, (C3) 6 μg/mL, (C4) 8 μg/mL, (C5) 10 μg/mL), (C6) 12 μg/mL, (C7) 14 μg/mL, (C8) 16 μg/mL, (C9) 18 μg/mL 
and (C10) 20 μg/mL; B: Representation of specificity based on UV-Vis absorbance spectra for the antibody interactions at equal concentrations of AGA and control 
antibody; C: Colorimetric response curve plotted on AuNP coated with peptide following the addition of AGA at different dilutions. AGA: Anti-gliadin.
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Testing clinical samples
The results for the 30 non­haemolytic, clinical samples 
were recorded after the visual examination of precipitate 
formation and determination of shift or change in absor­
bance values using a UV­vis spectrophotometer. Based 
on the results observed by eye, the samples have been 
divided into three categories: clear precipitation, aggre­
gation and colloidal suspension. 
The assay sensitivity was determined based on the 
colorimetric response obtained for each serum sample and 
is calculated as colorimetric response = Imax at 580 nm/Iat 527 nm. 
Using this method, the calculated colorimetric response for 
normal serum (serum without AGA) is 1 and this acts 
as the cut­off value. Therefore, for the clinical samples, 
based on the spectral absorbance data, a value of ≤ 
1 is indicated as negative for CD and a value above 1 
is indicated as CD positive. Based on the observation 
and calculation of the colorimetric response curve, we 
summarized the outcomes in Tables 1 and 2 and Figure 
5 along with the results reported using other serological 
methods, biopsy and histology.
DISCUSSION
The hexapeptide sequence QXQPFP (X being P, Q and 
L) within gliadin was previously identified as the domi-
nant epitope for IgA and IgG antibodies against dea­
midated gliadin peptides (a­DGP)[26]. This sequence 
overlaps with residues 57­62 of native α­gliadin and 
has been shown to occur with high specificity in sera 
from CD individuals[27,28]. The 17­mer peptide sequence 
(QLQPFPQPQLPYPQPQC) used as the antigen in our 
study is a small, 2 kDa molecular weight hexapeptide con­
taining sequence.
In order to use peptide to coat AuNPs and to develop 
an assay for AGA, we needed to overcome the potential 
problem of aggregation of the coated nanoparticles 
prior to adding the AGA in the test. This was achieved 
by using a long chain PEG linker containing Maleimide 
at the Ω­end and Biotin group at the α­end. Following 
the reaction of maleimide group with the thiol (­SH) side 
chain of the cysteine amino acid in the peptide sequence, 
the biotinylated and PEGylated peptide was added to the 
NeutrAvidin coated AuNPs leading to the formation of 
peptide coated AuNPs. The coating of peptide onto the 
AuNPs surface was examined by UV­vis measurements 
that was based on the observation of a change in the 
absorbance peak for the nanoparticle or a red­shift[29]. 
The UV­vis absorbance spectra showed that upon 
coating of peptide onto the AuNPs, there was a shift in 
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Figure 4  Detection of anti-gliadin in spiked human serum using peptide-coated AuNPs. A: Reduction in color from red to translucent as well as precipitate 
formation was observed in AuNP coated with peptide in the presence of AGA and serum at different concentrations (S1-S10). No reduction in color from red to 
translucent or precipitate formation was observed in AuNP coated with peptide in the presence of control IgG and serum (C1-C10); B: Colorimetric response curve 
plotted in AuNP coated with peptide in 1:20 diluted serum following the addition of AGA at different dilutions. AGA: Anti-gliadin.
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absorbance maximum from 525 nm to 527 nm (red­shift) 
(Figure 2A). Also, we did not observe any measurable 
decrease of absorbance at peak wavelength or increase 
of absorbance at long wavelengths (600­700 nm). These 
results indicate that no strong AuNP­to­AuNP interactions 
took place after being coated with peptide and were 
stable in a dispersed colloidal state with minimal aggre­
gation. In addition, a small peak at 210 nm was also 
observed following the binding of peptide to AuNPs, as 
observed in previous studies on peptide coating[30]. 
We further confirmed the absence of aggregation 
using DLS, that showed an increase in hydrodynamic dia­
meter from 20 nm to 28 nm following coating with pep­
tide (Figure 2B). The increase in hydrodynamic diameter 
is larger than that expected for a 2 kDa peptide sequence 
and can be attributed to the larger molecular weight (68 
kDa) NeutrAvidin that coated the AuNPs (Supplementary 
information S1) through the biotin­maleimide PEG linker. 
Since the hydrodynamic radius in solution compares 
directly to the molar mass of the protein[31], in this case, 
being the peptide sequence as well as NeutrAvidin, an 
increase in hydrodynamic radius to 28 nm can be cor­
related. High resolution TEM images of AuNPs coated 
with peptide showed a “halo” layer surrounding the 
surface of the nanoparticles indicating that coating of 
the gold with the peptide had occurred and this helped 
to confirm the peptide coating to AuNPs. The peptide 
coats the AuNPs as a monolayer with a sharp border with 
constant thickness on the gold nanoparticle surface[32].
To assess the capability of peptide­coated AuNPs 
to detect AGA, serial dilutions of rabbit anti­gliadin IgG 
polyclonal antibody in a range that normally exists in 
human serum, were tested[33]. A significant reduction 
in color as well as a shift in absorbance from 527 nm to 
580 nm with a decrease in the absorbance peak (Figure 
3), indicated that in the presence of the AGA there was 
an increase in the intermolecular association of the 
peptide coated AuNPs. These inter­particle interactions 
caused aggregation, leading to precipitation and a drop­
in absorbance. These results obtained for the peptide 
coated AuNPs­AGA interaction are consistent with pre­
vious work, on the addition of specific analytes, such as 
metal ions, to citrate stabilised gold nanoparticles[34,35]. 
Spiked human serum containing 2­20 μg/mL AGA was 
then incubated with the peptide coated AuNPs. An in­
creased aggregation and precipitation, which was easily 
detectable by eye in the presence of the AGA was ob­
served (Figure 4). No color change or precipitation was 
observed in the serum spiked with normal IgG rabbit. 
Peptide­coated AuNPs were next tested in a selected 
set of human serum samples obtained from patients with 
CD or controls without CD. The main aim was to clearly 
distinguish the CD affected from the non­CD affected. To 
achieve that, serum was diluted with PBS, concentrated, 
purified and then allowed to react with AuNPs coated 
with peptide. This ensured that the range of the AGA in 
the sera fell in the peak sensitivity range (2­20 μg/mL).
Out of the thirty samples analysed, fourteen samples 
that were diagnosed with active CD with high antibody 
titres as shown by serology and intestinal damage as per 
biopsy were identified as CD positive using AuNP-Peptide-
AGA assay as well. These samples showed the formation 
of a precipitate and had a clear shift as well as drop in 
UV­vis absorbance values as well as a high colorimetric 
response value (refer Table 1). The remaining samples 
were then classified into various sub­classes based on 
the analysis using the AuNP­Peptide­AGA assay as de­
scribed below (refer Tables 1 and 2, Figure 5).
The AuNP­Peptide­AGA assay could correctly identify 
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Figure 5  Representation of the distribution of clinical samples using AuNP-peptide-anti-gliadin test.
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Type 1 diabetes (T1DM), as positive for CD and this 
result matched with the previously conducted biopsy and 
serology profile of the patient. In comparison, an existing 
commercially available point­of­care test, SimtomaX® 
blood drop (Augurix diagnostics) that uses a combination 
of three different peptides as the DGP antigens was 
found to be less specific in diagnosing CD in children suf-
fering from T1DM[36]. 
The elevated risks of patients with T1DM to develop 
celiac disease arises because of multiple environmental 
and immunological factors and common genetic back­
ground[37]. The prevalence of celiac disease in T1DM is 
reported high with a mean prevalence rate of 8%[38] 
making regular monitoring of patients, particularly chil­
dren with T1DM a necessity. AuNP­Peptide­AGA diag­
nostic assay shows improved specificity over the existing 
point­of­care test based on DGP. This test result shows 
immense potential of the assay in pre­selecting CD suf­
ferers particularly those belonging to high­risk pediatric 
populations and, therefore, needs to be further explored 
in large clinical studies.
The cohort of tested samples included two cases 
where the patients had previously been diagnosed with 
CD and therefore followed a gluten free diet (GFD). 
While one person had been on a GFD for more than 8 
wk (volunteer number n.11), the other person had been 
on a GFD for less than 2 wk (volunteer number n.12). 
While the conventional serology test identified these two 
patients as negative, the peptide­based assay obtained 
a positive for CD that is similar to the diagnosis based on 
mucosal biopsy. 
A clear precipitate using the AuNP­Peptide­AGA assay 
was obtained for three samples (volunteer numbers 
n.24, n.25, n.26, Table 2) with patchy/irregular mucosal 
lesions, classified as a broad sub­type of potential or 
latent celiac. The UV­vis absorbance data supported the 
visual examination. These three samples were classified 
as positive for CD as these may be latent celiac sufferers 
that initially, display mild mucosal atrophy, that then 
develops to typical atrophy of small intestine mucosa 
along with a presentation of positive CD serology[39].
Aggregation of nanoparticles along with a drop in UV­
vis absorbance values was demonstrated by four clinical 
samples (volunteer numbers n.27, n.28, n.29, n.30, 
Table 2). These samples had positive or low positive 
serology along with mucosal inflammation. The AuNP­
Peptide­AGA assay showed results similar to those 
found using the existing serological assays. These four 
cases have been identified as “potential” CD positives, a 
subtype of CD that displays a normal villous architecture 
but also shows clinical symptoms, such as increased γδ+ 
intraepithelial lymphocytes along with the presence of 
gliadin specific antibodies, that are mostly at low titres (< 
1:40)[40]. Potential CD cases are often difficult to diagnose 
by histology which has a lowered predictive value in 
recognizing such cases. Correct diagnosis for potential 
CD cases therefore necessitates an evaluation of both 
serological markers as well as pathological symptoms.
The cohort included four samples identified as nega-
tive for CD based on biopsy and existing serology tests 
(volunteer numbers n.2, n.13, n.20 and n.21, Table 1). 
Out of the four samples, two samples were correctly 
identified as CD negative by AuNP­Peptide­AGA assay 
while the other two samples showed the formation of 
aggregates and were identified as positive (volunteer 
numbers n.2 and n.20). As intestinal biopsy has been 
used as the gold standard for CD confirmation, these two 
samples have been referred to as a false positive. 
Overall, upon comparing the results for the 30 clinical 
samples, while 26 samples were interpreted similar to 
the analysis using the existing serology and histology, 2 
false positive results and 2 false negative results were 
obtained using the AuNP­Peptide­AGA assay giving the 
AuNP­Peptide­AGA assay an overall accuracy of 86.6%.
Celiac disease is induced by the protein gliadin, 
present in wheat and some other cereals causing dam­
age to the small intestine. In the present study, we 
demonstrated that a peptide sequence derived from 
gliadin in conjunction with AuNPs can be used as an ef­
ficient tool to detect a biomarker for CD from serum. 
This was achieved by developing a methodology to coat 
the small antigenic peptide sequence on the surface 
of AuNPs without causing aggregation. A color change 
and absorbance peak shift caused by the aggregation 
of AuNPs was observed following the addition of AGA to 
peptide coated AuNPs at levels associated with CD. We 
confirmed that the developed assay can detect AGA not 
only in quantitatively spiked samples but also in a small­
scale study on real non­hemolytic CD patient’s samples. 
The present study shows that this novel peptide 
functionalised AuNP based assay is useful for pre­
selecting CD diseases particularly in high­risk pediatric 
populations that can be then confirmed by mucosal 
biopsy. The developed assay has high accuracy levels 
and is relatively cheaper to develop, the assay format 
has potential to be adapted as point­of­care test that 
would be useful in an exclusion diagnostic strategy as 
positive result would strengthen the possibility of CD that 
can be confirmed using intestinal biopsy. 
ARTICLE HIGHLIGHTS
Research background
Celiac disease is a chronic immune mediated disorder of the small intestine 
caused by consuming the protein gluten present in wheat and some other 
cereals. Following the activation of the innate immune system, a number of 
cytokines as well as antibodies are released in celiac patients that can be used 
as specific biomarkers to develop diagnostic tests. Over the years, a number 
of diagnostic tests have been developed, however, in spite of the good initial 
results in terms of sensitivity and specificity, when these tests are used on a 
large scale they have lowered predictive values. In the present study, a novel 
assay using peptide functionalised gold nanoparticles was developed that can 
be useful in an exclusion based diagnostic strategy.
Research motivation
The number of celiac disease sufferers are rapidly increasing throughout the 
world, and there is an increased need for newer detection methods that are 
easy to use, accurate as well as cheaper to enable early identification of the 
disease. The present study addresses this issue through the development of 
a novel assay combining the unique properties of gold nanoparticles with the 
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specificity of the antibodies. The developed assay shows great potential to 
be developed as a point-of-care test that would be beneficial for large scale 
screening of celiac disease. 
Research objectives 
In order to develop a celiac diagnostic assay based on the properties of the 
gold nanoparticles combined with the specificity of the antibodies from serum 
the following aims have been addressed in this work: (1) To develop method for 
the binding and adsorption of peptide derived from gliadin, the main antigenic 
protein causing celiac disease on the surface of gold nanoparticles; (2) to 
detect and measure the concentrations of antibodies to be used as biomarkers 
in serum; (3) to test and validate the developed test on real patient serum 
samples.
Research methods
The peptide coated gold nanoparticles were characterized using UV-vis 
spectra, dynamic light scattering and transmission electron microscopy. The 
UV-vis absorbance readings of peptide coated AuNPs following interactions 
with AGA and IgG from rabbit serum (control antibody) were used to calculate 
the percentage absorbance values. The students t-test was used to compare 
the sets of quantitative data that were collected independently of one another 
to calculate the p value and determine statistical significance. The assay 
sensitivity was determined based on the colorimetric response values. 
The clinical accuracy of the peptide coated AuNPs was determined using 
a selected, varied set of thirty human serum samples obtained from patients 
with celiac disease or controls without celiac disease. The results for the thirty 
clinical samples were recorded after the visual examination of precipitate 
formation and the determination of a shift or change in absorbance values using 
a UV-vis spectrophotometer. The assay sensitivity was determined based on 
the colorimetric response values obtained for each serum sample. 
Research results
The peptide sequence was successfully coated to the AuNP and characterization 
methods indicated that a stable colloidal suspension of the peptide coated AuNPs 
was achieved that was sustained by the high affinity biotin-avidin interactions. 
The addition of anti-gliadin antibody to peptide coated AuNPs as well as 
in spiked serum at a threshold level resulted in lowering as well as a shift of 
absorbance peaks that indicated the aggregation of AuNPs. On the other hand, 
in the presence of a non-specific, normal IgG antibody there was no interaction 
between the peptide coated AuNPs, with no reduction in color or shift in 
wavelength or aggregation of AuNPs. 
The clinical accuracy of the peptide coated AuNPs was tested using 30 
clinical samples, where 26 samples were shown to have the same analysis 
as that obtained with existing serology and histology, however, 2 false positive 
results and 2 false negative results were also obtained using the AuNP-peptide-
AGA assay giving the AuNP-peptide-AGA assay an overall accuracy of 86.6%.
Research conclusions
In this study, we demonstrate the potential of peptide functionalised gold 
nanoparticles as a colorimetric sensor for screening celiac disease. The AuNP-
peptide assay seems promising for development as a point-of-care test, this 
is because it is based on the formation of a precipitate as well as a reduction 
in color for a positive sample in the presence of a celiac disease specific 
autoantibody, thereby, eliminating the need for secondary antibody. This greatly 
reduces the cost of development for the assay and would be a step in the 
direction of one-step detection for celiac disease based on single antibody 
detection. 
Research perspectives
The AuNP-Peptide based approach shows great potential and would be 
particularly useful in aiding large-scale screening of the general population, 
particularly in the pre-selection of young Celiac disease (CD) sufferers which 
can be then confirmed by mucosal biopsy. A positive result would strengthen the 
possibility of CD while a negative test would help avoid unnecessary intestinal 
biopsy thereby reducing the economic burden on healthcare resources resulting 
in cost savings.
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